Additional information:
VUN65671is a Potent Entry Inhibitor of Ebola and Marburg Virus Infections. VUN65671 was reported in Journal of Medicinal Chemistry (2020), 63(13), 7211-7225.|Product information|CAS Number: 2479465-67-1|Molecular Weight: 461.52|Formula: C25H30F3N3O2|Synonym:|VUN-65671|VUN65671|VUN 65671|Chemical Name: Benzamide,N-[4-(4-methyl-1-piperidinyl)-3-(trifluoromethyl)phenyl]-4-(4-morpholinylmethyl)-|Smiles: CC1CCN(CC1)C1=CC=C(C=C1C(F)(F)F)NC(=O)C1C=CC(CN2CCOCC2)=CC=1|InChiKey: VVJSZYWIEBDKTC-UHFFFAOYSA-N|InChi: InChI=1S/C25H30F3N3O2/c1-18-8-10-31(11-9-18)23-7-6-21(16-22(23)25(26,27)28)29-24(32)20-4-2-19(3-5-20)17-30-12-14-33-15-13-30/h2-7,16,18H,8-15,17H2,1H3,(H,29,32)|Technical Data|Appearance: Solid Power.|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Lanreotide} web|{Lanreotide} Biological Activity|{Lanreotide} Purity|{Lanreotide} supplier|{Lanreotide} Epigenetics} |Shelf Life: ≥360 days if stored properly.{{Sirukumab} site|{Sirukumab} Interleukin Related|{Sirukumab} Protocol|{Sirukumab} In Vivo|{Sirukumab} custom synthesis|{Sirukumab} Autophagy} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:23514335 |Drug Formulation: To be determined.|HS Tariff Code: 382200|How to use|In Vitro:|EBOV/MARV-IN-1 (12.5 µM; 48 h) inhibits HIV/EBOV-GP (EC50=12 nM) and HIV/MARV-GP (EC50=180 nM) pseudotype virus in A549 cells containing a luciferase reporter gene, with low cytotoxicity (SI =2088).|References:|Gaisina IN, et, al. Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections. J Med Chem. 2020 Jul 9;63(13):7211-7225.Products are for research use only. Not for human use.|